Palantir sues ex-engineers for allegedly stealing trade secrets to start rival AI firm Percepta, backed by venture capital.
Vulcan Materials reports strong Q3 results, expects continued growth in construction materials demand driven by infrastructure spending.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
Palantir sues ex-engineers for allegedly stealing trade secrets to start rival AI firm Percepta, backed by venture capital.
Vulcan Materials reports strong Q3 results, expects continued growth in construction materials demand driven by infrastructure spending.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.